Development of Specific Diagnostic Tools for Cardiac Insufficiency With Preserved Ejection Fraction
NCT ID: NCT04699890
Last Updated: 2025-09-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
91 participants
OBSERVATIONAL
2022-01-11
2025-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Right Ventricular Function and Pulmonary Hypertension in HFpEF
NCT05055180
Diagnosing Heart Failure With Preserved Ejection Fraction in Patients With Unexplained Dyspnea (Diagnose-HFpEF)
NCT04688905
Mechanisms of Right Ventricular Adaptation in Patients With Heart Failure With Preserved Ejection Fraction
NCT04154657
Prospective Study of Heart Failure With Preserved Left Ventricular Ejection Fraction
NCT01091467
Echocardiographic Assessment and CLInical imPlication of Functional tricuSpid rEgurgitation in Heart Failure With Reduced or Preserved Ejection Fraction
NCT05209919
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
preserved ejection fraction
Patients with a preserved ejection fraction (HF / FEp)
Blood sampling, questionnaires and specific exams
Patients will have additionnal blood samples, answer to self-questionnaires and will performed an electrocardiogram and an echocardiography if not performed in routine care.
reduced ejection fraction
Patients with a reduced ejection fraction (HF / FEr)
Blood sampling, questionnaires and specific exams
Patients will have additionnal blood samples, answer to self-questionnaires and will performed an electrocardiogram and an echocardiography if not performed in routine care.
without heart failure
Patient without heart failure
Blood sampling, questionnaires and specific exams
Patients will have additionnal blood samples, answer to self-questionnaires and will performed an electrocardiogram and an echocardiography if not performed in routine care.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sampling, questionnaires and specific exams
Patients will have additionnal blood samples, answer to self-questionnaires and will performed an electrocardiogram and an echocardiography if not performed in routine care.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* heart failure (NT-proBNP ≥ 450 pg/mL during hospitalization or follow-up)
* echocardiography showing an ejection fraction ≥ 50%,
* patients already hospitalized and followed in cardiology consultation,
* patients agreeing to sign informed consent,
* patient affiliated to french health care system.
* Age \> or = 65,
* heart failure (NT-proBNP ≥ 450 pg/mL during hospitalization or follow-up)
* echocardiography showing an ejection fraction \< 50%,
* patients already hospitalized and followed in cardiology consultation,
* patients agreeing to sign informed consent,
* patient affiliated to french health care system.
* Age \> or = 65,
* patients already hospitalized and followed in cardiology consultation for one of the following pathology : stable coronaropathy without heart failure, arterial hypertension without heart failure, auricular fibrilation without heart failure
* patients agreeing to sign informed consent,
* patient affiliated to french health care system.
Exclusion Criteria
* any condition leading to a prognosis of less than 7 days,
* Known hepatocellular insufficiency, or known hepatic cirrhosis
* ASAT / ALAT\> 10N excluding cardiac cause
* Any conditions that may put the patient at risk or increase the risk of non-compliance with the protocol or lost to follow-up according to the opinion of the investigator
* Patient under legal protection, under guardianship or under curatorship
* Inability to give the subject informed information
* Pregnant or breastfeeding woman
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Montpellier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sylvain Aguilhon, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Montpellier
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Montpellier
Montpellier, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-A02216-33
Identifier Type: REGISTRY
Identifier Source: secondary_id
RECHMPL18_0466
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.